AARD — Stock Film
STOCK FILMSCENE 1/11AARD · $6.82
Stock Expert AI presents
AARD
Aardvark Therapeutics, Inc. Common Stock
~4 min film100% real numbers0 jargon
WHAT DOES THIS COMPANY DO?
Aardvark Therapeutics, Inc. Common Stock. A quick introduction.

On the stock market since 2025, it operates in the world of health and science. It has 22 employees. Now — the numbers.

on the stock market since 2025
22 employees
$110.8M market value
Revenue last year:
$0
The loss that same year:
$0
Sales don’t cover the costs; the gap drains from the cash pile every year.

The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.

In the vault right now:
$0
DEBT: $441K
At this pace, that money lasts about 1.9 years.

Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.

Every quarter, analysts set a profit bar.
How many of the last 7 did the company clear?
3 / 7
EXPECTATIONS MET OR BEATEN
3
Mar 2025
May 2025
Aug 2025
Nov 2025
Mar 2026
May 2026
Aug 2026
3 TIMES IN THE LAST 7 QUARTERS
It misses the bar more often than not.
INSIDE THE REPORT CARD

We compared this company with its own sector across five subjects.

A score of 50 means class average.

BUSINESS QUALITY
23
very weak

Clearly below the class average.

FINANCIAL STRENGTH
44
weak

Clearly below the class average.

VALUATION
6
very weak

Clearly below the class average.

GROWTH
7
very weak

Clearly below the class average.

PRICE MOMENTUM
27
very weak

Clearly below the class average.

WORTH WATCHING

Valuation: The stock trades at a price that looks expensive next to its earnings; that can cap future returns.

Growth: Sales growth trails the sector average.

THE COUNCIL REVIEW
9

angles, checked one by one.

The 2 that stand out are on screen; the rest came back neutral.

The council scores out of 10; report-card grades are out of 100.

WEAK SPOTS
The stock has lost its spark0/10
Thin profit on each sale3/10
WORTH WATCHING

Profit per Sale: The profit kept from each sale is thin.

THE FIVE-YEAR JOURNEY
A big climb, then a hard fall.

An investor who bought at the very peak is down 61% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.

1
THE BRIGHT SIDE · 1/2
Strong cash, light debt

There is $110.0M in the vault; even if every debt were paid off, $109.6M would remain.

2
THE BRIGHT SIDE · 2/2
Executives are buying their own stock

Over the last 12 months, company executives reported 19 buys and 6 sells. Management buying with its own money is usually read as a good sign.

1
THE RISKS · 1/3
Small sales, big loss

A loss of $57.6M against $0 in annual sales.

2
THE RISKS · 2/3
A wildly swinging price

This stock swings about 3.1 times as much as the market average. Big rallies — and big drops — can both happen fast.

3
THE RISKS · 3/3
The cash has a countdown

At the current pace of spending, the cash lasts about 1.9 years. After that, the company needs to find new money.

FINALE · THE GRADE
D
0 / 100 · MoonshotScore

On our five-subject report card, AARD sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”

The takeaway: AARD is a high-risk stock — not yet profitable, and its future rides on its product catching on.

The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.

What would you like to do next?
Open the stock page →
This was a film — not investment advice.
Data: FMP & company filings
Aug 22, 2026 · stockexpertai.com · Stock Film